Article Text

AB0377 Endothelial Dysfunction in Patients with Rheumatoid Arthritis Combined with Hypertension and its Correction with L-Arginine Aspartate
  1. O. Sirenko1,
  2. O. Kuryata1,
  3. T. Lysunets2
  1. 1State Establishment “Dnipropetrovsk medical academy of Health Ministry of Ukraine”
  2. 2Dnipropetrovsk Regional Hospital after Mechnikov, Dnipropetrovsk, Ukraine


Background As known, rheumatoid arthritis (RA) is associated with accelerated atherosclerosis development. Traditional modifiable risk factors such as hypertension and endothelial dysfunction and its correcrion plays a significant role in RA pts.

Objectives We aimed to evaluate the effects of L-Arginine on endothelial function and blood pressure control in RA patients combined with hypertension.

Methods 42 patients (4 M, 38 F, mean age – 54,11±2,64 years) with RA combined with hypertension were enrolled. The average duration of RA was 8,05±0,69 years, the mean DAS28 - 2,74±0,16. 21 (50%) patients received the standard treatment and L-Arginine aspartate 30 ml/day during 4-6 weeks (study group), while 21 (50%) (control group) – received only the standard treatment based on ACE inhibitors. Blood pressure, endothelial-dependent flow mediated vasodilatation of brachial artery were measured in all patients at baseline and to the end of the study.

Results Endothelial-dependent flow mediated vasodilatation lesion was established in the majority of patients – 30 (71.43%), mean level 6.13±2.41%. After 4-6 weeks of treatment with L-Arginine mean endothelial-dependent flow mediated vasodilatation was 10,16±2.51% compared with standard therapy – 6.97±1.84% (p<0.05). Endothelial function had been normalized in 9 (43%) patients and increased by 46,36%. The level of mean blood pressure to the end of the study was significantly lower among patients of study group (128.4±3.5 vs 134.2±3.1, p<0.05).

Conclusions L-Arginine aspartate significantly improves endothelial function and has an additional hypotensive effect in rheumatoid arthritis patients with hypertension.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.